Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

7T MRI Scan for the Early Detection of Melanoma Brain Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04941430
Recruitment Status : Not yet recruiting
First Posted : June 28, 2021
Last Update Posted : June 28, 2021
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Southern California

Brief Summary:
This clinical trial studies the use of 7-Tesla (7T) magnetic resonance imaging (MRI) in detecting melanoma that has spread to the brain (melanoma brain metastases). The standard MRI brain imaging is done on 3T or similar MRI machine, but the 7T MRI machine has a larger magnet which has been shown to have superior resolution of the brain and of non-cancerous brain lesions. Diagnostic procedures such as 7T MRI may help find and diagnose melanoma brain metastases earlier than standard 3T MRI.

Condition or disease Intervention/treatment Phase
Clinical Stage IV Cutaneous Melanoma AJCC v8 Metastatic Malignant Neoplasm in the Brain Metastatic Melanoma Pathologic Stage IV Cutaneous Melanoma AJCC v8 Diagnostic Test: Magnetic Resonance Imaging using 7 Tesla MRI Not Applicable

Detailed Description:

PRIMARY OBJECTIVE:

I. Assess the potential superiority of contrast-enhanced (CE) 7T MRI by comparing to standard of care CE 3T MRI in detecting occult brain metastases lesion at time of diagnosis of new brain metastases.

SECONDARY OBJECTIVE:

I. Describe the imaging characteristics of melanoma brain metastases on 7T MRI of the brain.

EXPLORATORY OBJECTIVE:

I. Evaluate incidence of diagnosis of leptomeningeal disease on CE 7T MRI brain.

OUTLINE:

Within 2 weeks of initial standard of care 3T MRI, patients undergo 7T MRI scan with and without contrast over 1-2 hours.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Pilot Study of 7T MRI for Early Diagnosis of Melanoma Brain Metastases
Estimated Study Start Date : July 1, 2021
Estimated Primary Completion Date : July 1, 2023
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: MRI Scans Melanoma

Arm Intervention/treatment
Experimental: Diagnostic (7T MRI)
Within 2 weeks of initial standard of care 3T MRI, patients undergo 7T MRI scan with and without contrast over 1-2 hours.
Diagnostic Test: Magnetic Resonance Imaging using 7 Tesla MRI
Undergo 7T MRI
Other Names:
  • 7 Tesla MRI
  • 7T MRI




Primary Outcome Measures :
  1. Presence or absence of brain metastases on 7 tesla (T) magnetic resonance imaging (MRI) as compared to the standard of care 3T MRI [ Time Frame: Up to 14 days ]
    Any visualized brain metastases seen in this study on 3T will be evaluated using the criteria proposed by the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM). As there are no consensus criteria for 7T MRI published at this time, we will apply the same RANO-BM criteria to the study 7T MRI exams.Will count the discordant lesions between 3T and 7T, i.e. lesion identified in 7T but not 3T (L71L30) versus (vs.) lesion identified in 3T but not 7T(L70L31). McNemar's test will be used to compare L71L30 vs. L70L31. Will report 95% Clopper Pearson exact confidence interval for L71L30 vs. L70L31 in incidence of diagnosis of leptomeningeal disease.

  2. Primary tumor size [ Time Frame: Up to 14 days ]
    Measured by study contrast enhanced (CE) 7T MRI compared to standard of care 3T MRI.


Other Outcome Measures:
  1. Incidence of diagnosis of leptomeningeal disease on CE 7T MRI brain [ Time Frame: At baseline ]
    Spaghetti plots will be used to illustrate the radiographic patterns of unique tumors.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Melanoma patients with new untreated brain metastases seen on CE 3T MRI
  • Patient may have received previous systemic therapy, immunotherapy, or checkpoint inhibitors
  • Patient may have previous brain metastases treated >30 days prior with brain radiation, either whole brain radiation or radiosurgery
  • Age >= 18 years
  • Karnofsky performance status (KPS) >= 70
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Women of child-bearing potential need negative urine human chorionic gonadotropin (hCG) within 2 weeks prior to any treatment. A female of child-bearing potential is defined as any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

    • Has not undergone a hysterectomy or bilateral oophorectomy; or
    • Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
  • Ability to tolerate MRI (able to lie flat in supine position without undue anxiety or discomfort or history of claustrophobia)
  • Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

  • Patients who have had brain neurosurgery =< 30 days prior to entering the study or those who have not recovered from adverse events related to that procedure
  • Patients who have had central nervous system (CNS)-directed radiotherapy =< 30 days prior to entering the study or those who have not recovered from adverse events due to agents administered more than 30 days earlier
  • Patients with claustrophobia or anxiety limiting ability to tolerate MRI scans. Unable to tolerate MRI scan without use of anxiolytic medication or with distress requiring termination of scan or resulting in scans of poor quality
  • Patients with MRI-incompatible pacemakers or MRI-incompatible implants
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to gadolinium-based contrast agents (GBCA) or other agents used in study
  • Patients with poor renal function (estimated glomerular filtration rate [eGFR] < 30) or requiring dialysis
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04941430


Contacts
Layout table for location contacts
Contact: Lindsay Hwang 323-409-5010 Lindsay.Hwang@med.usc.edu

Locations
Layout table for location information
United States, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Contact: Lindsay Hwang    323-409-5010    Lindsay.Hwang@med.usc.edu   
Principal Investigator: Lindsay Hwang         
Sponsors and Collaborators
University of Southern California
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Lindsay Hwang University of Southern California
Layout table for additonal information
Responsible Party: University of Southern California
ClinicalTrials.gov Identifier: NCT04941430    
Other Study ID Numbers: 10M-20-1
NCI-2021-05850 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
10M-20-1 ( Other Identifier: USC / Norris Comprehensive Cancer Center )
P30CA014089 ( U.S. NIH Grant/Contract )
First Posted: June 28, 2021    Key Record Dates
Last Update Posted: June 28, 2021
Last Verified: June 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Neoplasms
Neoplasms
Skin Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Melanoma
Nevi and Melanomas
Central Nervous System Diseases
Nervous System Diseases
Skin Diseases